Alvotech News and Activities

Acquisition, funding and merger involving Alvotech.

• Alvotech has just announced a $165 Million fundraising (posted on June 19 2026).

View the org chart displaying its 33 main executives

Most searched biographies at Alvotech

• Lisa Graver, Chief Executive Officer
• Tomas Ekman, Director
• Ann Merchant, Independent Director

Popular executive movements at Alvotech

• Tanya Zharov, General Counsel, has left the company  (posted on May 4 2026).
• Johan Van Der Putten, Vice President, Global Procurement, has left the company  (posted on April 6 2026).
• Robert Wessman, Executive Chairman and Chief Executive Officer , will leave the company on Mar. 31, 2026  (posted on January 7 2026).

Click here to view some more movements at Alvotech

Create your alert
to follow the executive moves at Alvotech.

Alvotech has 2,414 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
• Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).
• Osanni Bio has just announced a $190 Million fundraising (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Alvotech

• Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement | Alvotech
• Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement | Alvotech
• Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares | Alvotech
• Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® | Alvotech
• Transactions of Managers and Closely Associated Persons | Alvotech
• Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® | Alvotech
• Alvotech to present at upcoming investor conferences in June | Alvotech
• Main Results of 2026 Annual and Extraordinary General Meeting | Alvotech
• Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland | Alvotech
• Alvotech announces completion of FDA surveillance inspection at Reykjavik facility | Alvotech
• View more press releases Close

Social media about Alvotech

• Alvotech on Wikipedia, Google News & Yahoo Finance
• Alvotech on LinkedIn, X (Twitter) & YouTube